Myeloma—the Elusive Cure

References

• Cohen, H. J. and Rundles, R. W. (1975). Managing the complications of myeloma, Arch Int Med, 135, 177–184.
   PubMedGoogle Scholar
• Durie, B. G. and Salmon, S. E. (1975). A clinical staging system for multiple myeloma, Cancer, 36, 842–853.
   PubMed Web of Science ®Google Scholar
• Alexanian, R. (1980). Treatment of multiple myeloma, Acta Haemat, 63, 237–240.
   PubMed Web of Science ®Google Scholar
• Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. and Vesole, D. (1998). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation, Br J Haem, 102, 1115–1123.
   PubMed Web of Science ®Google Scholar
• Alexanian, R., Bergsagel, D. E., Migliore, P. J., Vaughn, W. K. and Howe, C. D. (1968). Melphalan therapy for plasma cell myeloma, Blood, 31, 1–9.
   PubMed Web of Science ®Google Scholar
• George, R. P., Poth, J. L., Gordon, D. and Schrier, S. L. (1972). Multiple myeloma—intermittent combination chemotherapy compared to continuous therapy, Cancer, 29, 1665–1670.
   PubMed Web of Science ®Google Scholar
• Rivers, S. L. and Patno, M. E. (1969). Cyclophosphamide. vs melphalan in treatment of plasma cell myeloma, JAMA, 207, 1328–1334.
   PubMed Web of Science ®Google Scholar
• Chen, Y. H., Shiao, R. T., Labayog, J. M., Modi, S. and Lavelle, D. (1997). Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma, Leak Lymphoma, 27, 11–23.
   PubMed Web of Science ®Google Scholar
• Alexanian, R., Haut, A., Khan, A. U., Lane, M., McKelvey, E. M., Migliore, P. J., Stuckey, J. and Wilson, H. E. (1969). Treatment for multiple myeloma, JAMA, 208, 1680–1685.
   PubMed Web of Science ®Google Scholar
• Alexanian, R., Dimopoulos, M. A., Delasalle, K. and Barlogie, B. (1992). Primary dexamethasone treatment of multiple myeloma, Blood, 80, 887–890.
   PubMed Web of Science ®Google Scholar
• Boccadoro, M. and Pileri, A. (1997). Diagnosis, prognosis and standard treatment of multiple myeloma, Hematol Oncol Clin North Am, 11, 111–131.
   PubMed Web of Science ®Google Scholar
• MacLennan, I. C., Chapman, C., Dunn, J. and Kelly, K. (1992). Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis, Lancet, 339, 200–205.
   PubMed Web of Science ®Google Scholar
• Alexanian, R. and Dreicer, R. (1984). Chemotherapy for multiple myeloma, Cancer, 53, 583–588.
   PubMed Web of Science ®Google Scholar
• MacLennan, I. C. and Cusick, J. (1985). Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis, Br J Cancer, 52, 153–158.
   PubMed Web of Science ®Google Scholar
• Boccadoro, M., Marmont, F., Tribalto, M., Avvisati, G., Andriani, A., Barbui, T., Cantonetti, M., Carotenuto, M., Comotti, B., Dammacco, F., Frieri, R., Gallamini, A., Gallone, G., Giovangrossi, P., Grignani, F., Lauta, V. M., Liberati, M., Musto, P., Neretto, G., Petrucci, M. T., Resegotti, L., Pileri, A. and Mandelli, F. (1991). Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisolone even in high-risk patients, J Clin Oncol, 9, 444–448.
   PubMed Web of Science ®Google Scholar
• Hjorth, M., Hellquist, L., Holmberg, E., Magnusson, B., Rodjer, S. and Westin, J. (1990). Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisolone, Br J Haem, 74, 185–191.
   PubMed Web of Science ®Google Scholar
• Gregory, W. A., Richards, M. A. and Malpas, J. S. (1992). Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials, J Clin Oncol, 10, 334–342.
   PubMed Web of Science ®Google Scholar
• Durie, B. G., Dixon, D. O., Carter, S., Stephens, S., Bonnet, R. J., Salmon, S. E., Dabich, L., Files, J. C. and Costanzi, J. J. (1986). Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group study, J Clin Oncol, 4, 1227–1237.
   PubMed Web of Science ®Google Scholar
• Harley, J. B., Pajak, T. F., McIntyre, O. R., Kochwa, S., Cooper, M. R., Coleman, M. and Cuttner J. (1979). Improved survival of increased risk myeloma patients on combined triple alkylating agent therapy: A study of the CALGB, Blood, 54, 13–22.
   PubMed Web of Science ®Google Scholar
• Samson, D., Gaminara, E., Newland, A., Van de Pette, J., Kearney, J., McCarthy, D., Joyner, M., Aston, L., Mitchell, T., Hamon, M., Barrett, A. and Evans, M. (1989). Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma, Lancet, ii, 882–885.
   Google Scholar
• Cook, G., Marinaki, P., Farell, E., Pearson, C., Alcorn, M. J., Sharp, R. A., Tansey, P. J. and Franklin, I. M. (1997). Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy, Leukemia, 11(suppl 5), S35–40.
   PubMedGoogle Scholar
• Cook, G., Sharp, R. A., Tansey, P. and Franklin, I. M. (1996). A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma, Br J Haem., 93, 931–934.
   PubMed Web of Science ®Google Scholar
• McElwain, T. J. and Powles, R. L. (1983). High-dose intravenous melphalan for plasma-cell leukaemia and myeloma, Lancet ii, 822–824.
   Google Scholar
• Barlogie, B., Alexanian, R., Smallwood, L., Cheson, B., Dixon, D., Dicke, K. and Cabanillas, F. (1988). Prognostic factors with high-dose melphalan for refractory multiple myeloma, Blood, 72, 2015–2019.
   PubMed Web of Science ®Google Scholar
• Selby, P. J., McElwain, T., Nandi, A., Perren, T., Powles, R., Tillyer, C., Osborne, R., Slevin, M. and Malpas, J. (1987). Multiple myeloma treated with high dose intravenous melphalan, Br J Haem, 66, 55–62.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Hall, R., Zander, A., Dicke, K. and Alexanian, R. (1986). High-dose melphalan with autologous bone marrow transplantation for multiple myeloma, Blood, 67, 1298–1301.
   PubMed Web of Science ®Google Scholar
• Guba, S. C., Vesole, D. H., Jagannath, S., Bracy, D., Barlogie, B. and Tricot, G. (1997). Peripheral stem cell mobilization and engraftment in patients over age 60, Bone Marrow Transplant, 20, 1–3.
   PubMed Web of Science ®Google Scholar
• Dumontet, C., Ketterer, N., Espinouse, D., Neidhardt, E. M., Moullet, I., Theblemont, C., Salles, G. and Coiffier, B. (1998). Reduced progression-free survival in elderly patients recieving intensification with autologous peripheral blood stem-cell reinfusion for multiple myeloma, Bone Marrow Transplant, 21, 1037–1041.
   PubMed Web of Science ®Google Scholar
• Harousseau, J. L., Attal, M., Divine, M., Milpied, N., Marit, G., Leblond, V., Stoppa, A. M., Bourhis, J. H., Caillot, D., Boasson, M., Abgrall, J. F., Facon, T., Colombat, P., Cahn, J. Y., Lamy, T., Troussard, X., Gratecos, N., Pignon, B. and Auzanneau, G. (1995). Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma, Bone Marrow Transplant, 15, 963–969.
   PubMed Web of Science ®Google Scholar
• Raje, N., Powles, R., Horton, C., Millar, B., Shepherd, V., Middleton, G., Kulkarni, S., Eisen, T., Mehta, J., Singhal, S. and Treleaven, J. (1997). Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma, Br J Cancer, 75, 1684–1689.
   PubMed Web of Science ®Google Scholar
• Barlogie, B. and Gahrton, G. (1991). Bone marrow transplantation in multiple myeloma, Bone Marrow Transplant, 7, 71–79.
   PubMed Web of Science ®Google Scholar
• Attal, M., Harousseau, J. L., Stoppa, A., Sotto, J., Fuzibet, J., Rossi, J., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. and Bataille, R. (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma, N Engl J Med, 335, 91–97.
   PubMed Web of Science ®Google Scholar
• Fermand, J., Ravaud, P., Chevret, S., Divine M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., Boccacio, C. and Brouet, J. (1998). High-dose therapy and autologous peripheral blood stem-cell transplantation in multiple myeloma: up front or rescue treatment? Results of a multicenter sequential randomized clinical trial, Blood, 9, 3131–3136.
   Google Scholar
• Attal, M., Huguet, F., Schlaifer, D., Payen, C., Laroche, M., Fournie, B., Mazieres, B., Pris, J. and Laurent, G. (1992). Intensive combined therapy for previously untreated aggressive myeloma, Blood, 79, 1130–1136.
   PubMed Web of Science ®Google Scholar
• Powles, R., Raje, N., Milan, S., Millar, B., Shepherd, V., Mehta, J., Singhal, S., Kulkarni, S., Viner, C., Gore, M., Cunningham, D. and Treleaven, J. (1997). Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment, Bone Marrow Transplant, 20, 435–443.
   PubMed Web of Science ®Google Scholar
• Jagannath, S., Barlogie, B., Dicke, K., Alexanian, R., Zagars, G., Cheson, B., Lemaistre, F., Smallwood, L., Pruitt, K. and Dixon, D. (1990). Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors, Blood, 76, 1860–1866.
   PubMed Web of Science ®Google Scholar
• Schiller, G., Vesico, R., Freytes, C., Spitzer, G., Sahebi, F., Lee, M., Wu, C., Cao, J., Lee, J. and Hong, C. H. (1995). Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma, Blood, 86, 390–397.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. and Tricot, G. (1997). Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma, Blood, 89, 789–793.
   PubMed Web of Science ®Google Scholar
• Attal, M., Harousseau, J. L., Facon, T., Michaux, J. L., Guilhot, F., Fruchard, C., Fuzibet, J. G., Hulin, C., Caillot, D., Dorvaux, V., Cahn, J. Y., Grobois, B., Stoppa, A. M., Ifrah, N., Sotto, J. J., Pignon, B. and Payen, C. (1999). Single versus double transplant in myeloma: a randomised trial of the “Inter Groupe Francais du Myelome” (IFM), Blood, 94(suppl. 1), 713a.
   PubMedGoogle Scholar
• Harousseau, J. L., Milpied, N., Laporte, J. P., Collombat, P., Facon, T., Casassus, P., Guilhot, F., Ifrah, N. and Gandhour, C. (1992). Double-intensive therapy in highrisk multiple myeloma, Blood, 79, 2827–2833.
   PubMed Web of Science ®Google Scholar
• Gahrton, G., Tura, S., Lljungman, P., Blade, J., Brandt, L., Cavo, M., Facon, T., Gratwohl, A., Hagenbeek, A., Jacobs, P., de Laurenzi, A., Vam Lint, M., Michallet, M., Nikoskelainen, J., Reiffers, J., Samson, D., Verdonck, L., de Witte, T. and Volin, L. (1995). Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma, J Clin Oncol, 13, 1312–1320.
   PubMed Web of Science ®Google Scholar
• Gahrton, G. (1996). Allogeneic bone marrow transplantation in multiple myeloma, Br J Haem, 92, 251–254.
   PubMed Web of Science ®Google Scholar
• Varterasian, M., Janakiraman, N., Karanes, C., Abella, E., Uberti, J., Dragovic, J., Raman, S. B., al-Katib, A., Du, W., Silver, S. M., Adams, P. T., Sensenbrenner, L. and Ratanatharathorn, V. (1997). Transplantation in patients with multiple myeloma: a multicentre comparative analysis of peripheral blood stem cell and allogeneic transplant, Am J Clin Onc, 20, 462–476.
   PubMed Web of Science ®Google Scholar
• Bentz, H., Burger, J. A., Kunzmann, R., Mertelsmann, R. and Finke, J. (1997). Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect, Leukemia, 11, 281–283.
   Web of Science ®Google Scholar
• Bjorkstrand, B., Ljungman, P., Svensson, H., Hermans, J., Alegre, A., Blade, J., Carlson, K., Cavo, M., Ferrant, A., Goldstone, A. H., de Laurenzi, A., Majolino, I., Marcus, R., Prentice, G., Remes, K., Samson, D., Sureda, A., Verdonck, L. F., Volin, L. and Gahrton, G. (1996). Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation, Blood, 12, 4711–4718.
   Google Scholar
• Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben Tal, O., Eldor, A. and Or, R. (1998). Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant haematologic diseases, Blood, 91, 756–763.
   PubMed Web of Science ®Google Scholar
• Belch, A., Shelley, W., Bergsagel, D., Wilson, K., Klimo, P., White, D. and Willan, A. (1988). A randomised trial of maintenance versus no maintenance melphalan and prednisolone in responding multiple myeloma patients, Br J Cancer, 57, 94–99.
   PubMed Web of Science ®Google Scholar
• Gisslinger, H. (1997). Interferon alpha in the therapy of multiple myeloma, Leukemia, 11, S52–56.
   PubMed Web of Science ®Google Scholar
• Abrahamson, G. M., Bird, J. M., Newland, A. C., Gaminara, E., Giles, C., Joyner, M., Kelsey, S. M., Lewis, D., McCarthy, D. M., Roques, A. W., Tew, C. J., Treacy, M., van de Pette, J. and Samson, D. (1996). A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma, Br J Haem, 94, 659–664.
   PubMed Web of Science ®Google Scholar
• Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gemone, A., Lauta, V. M., Marmont, F., Petrucci, M. T., Tribalto, M., Vegna, M. L., Dammacco, F. and Pileri, A. (1990). Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy, N Engl J Med, 322, 1430–1434.
   PubMed Web of Science ®Google Scholar
• Drayson, M. T., Chapman, C. E., Dunn, J. A., Olujohungbe, A. B. and MacLennan, I. C. (1998). MRC trial of interferon-alfa 2b maintenance therapy in first plateau phase of multiple myeloma, Br J Haem., 101, 195–202.
   PubMed Web of Science ®Google Scholar
• Wheatley, K. (1998). The role of interferon (IFN) as therapy for multiple myeloma: An overview of 24 randomised trials with over 4000 patients, J Clin Oncol, 17, 8a.
   Google Scholar
• Cunningham, D., Powles, R., Malpas, J., Raje, N., Milan, S., Viner, C., Montes, A., Hickish, T., Nicolson, M., Johnson, P., Treleaven, J., Raymond, J. and Gore, M. (1998). A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results, Br J Haem., 102, 495–502.
   PubMed Web of Science ®Google Scholar
• Lokhorst, H. M., Meuwissen, J. A., Bast, E. J. and Dekker, A. W. (1989). VAD chemotherapy for refractory multiple myeloma, Br J Haem., 71, 25–30.
   PubMed Web of Science ®Google Scholar
• Salmon, S. E., Dalton, W. S., Grogan, T. M., Plezia, P., Lehnert, M., Roe, D. J. and Miller, T. P. (1991). Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer, Blood, 78, 44–49.
   PubMed Web of Science ®Google Scholar
• Sonneveld, P., Durie, B. G., Lokhorst, H. M., Marie, J. P., Solbu, G., Suciu, S., Zitttoun, R. and Lowenberg, B. (1992). Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON, Lancet, 341, 558–559.
   Google Scholar
• Sonneveld, P., Lokhorst, H. M. and Vossebeld, P. (1997). Drug resistance in multiple myeloma, Semin Haematol, 34(suppl. 5), S34–39.
   PubMed Web of Science ®Google Scholar
• Colombat, P., Milpied, N., Laporte, J. P., Casassus, P., Linassier, C. and Harousseu, J. L. (1994). Three courses of high dose therapy. Feasibility in the treatment of multiple myeloma—a “France autogreffe” study, Cancer, 74, 2930–2934.
   PubMed Web of Science ®Google Scholar
• Oral idarubicin with CCNU and dexamethasone for relapsed myeloma: an effective oral regimen with minimal toxicity. Gupta, D., Kelsey, S. M., Littlewood, T. J., Giles, C., Newland, A. C. and Samson, D. (1996). Br J Haem, 93(suppl. 1), 81.
   PubMedGoogle Scholar
• Alexanian, R., Yap, B. S. and Bodey, G. P. (1983). Prednisolone pulse therapy for refractory myeloma, Blood, 62, 572–577.
   PubMed Web of Science ®Google Scholar
• Singer, C. R., Tobias, J., Giles, F., Rudd, G., Blackman, G. and Richards, J. (1989). Hemibody irradiation: an effective second line therapy in drug-resistant multiple myeloma, Cancer, 63, 2446–2451.
   PubMed Web of Science ®Google Scholar
• Bataille, R., Barlogie, B., Lu, Z., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J. and Klein, B. (1995). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma, Blood, 86, 685–691.
   PubMed Web of Science ®Google Scholar
• Niesvizky, R., Siegel, D. and Michaeli, J. (1993). Biology and treatment of multiple myeloma, Blood Rev, 7, 24–33.
   PubMed Web of Science ®Google Scholar
• Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddelmon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J. and Barlogie, B. (1999). Antitumor activity of thalidomide in refractory multiple myeloma, N Engl J Med, 341, 1565–1571.
   PubMed Web of Science ®Google Scholar
• Johnson, W. J., Kyle, R. A. and Dahlberg, P. J. (1980). Dialysis in the treatment of multiple myeloma, Mayo Clin Proc, 55, 65–72.
   PubMed Web of Science ®Google Scholar
• Ludwig, H., Fritz, E., Kotzmann, H., Hocker, P., Gisslinger, H. and Barnas, U. (1990). Erythropoietin treatment of anaemia associated with multiple myeloma, N Engl J Med, 322, 1693–1699.
   PubMed Web of Science ®Google Scholar
• Mill, W. B. and Griffith, R. (1980). The role of radiation therapy in the management of plasma cell tumours, Cancer, 45, 647–652.
   PubMed Web of Science ®Google Scholar
• Berenson, J. R. (1997). Bisphosphonates in multiple myeloma, Cancer, 80, 1661–1667.
   PubMed Web of Science ®Google Scholar
• McCloskey, E. V., MacLennan, I. C., Drayson, M. T., Chapman, C., Dunn, J. and Kanis, J. A. (1998). A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults, Br J Haem, 100, 317–325.
   PubMed Web of Science ®Google Scholar
• Lahtinen, R., Laakso, M., Palva, I., Virkkunen, P. and Elomaa, I. (1992). Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma, Lancet, 340, 1049–1052.
   PubMed Web of Science ®Google Scholar
• Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., George, S., Lipton, A., Ballester, O., Kovacs, M., Blacklock, H., Simeone, J. F., Reitsma, D. J., Heffeman, M., Seaman, J. and Knight, R. D. (1998). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group, J Clin Oncol, 16, 593–602.
   PubMed Web of Science ®Google Scholar
• Dhodapkar, M. V., Singh, J., Mehta, J., Fassas, A. and Desikan, K. R. (1998). Anti-myeloma activity of pamidronate in vivo, Br J Haem, 103, 530–532.
   PubMed Web of Science ®Google Scholar
• Body, J. J. (1997). Clinical research update: zolendronate, Cancer, 80, 1699–1701.
   PubMed Web of Science ®Google Scholar
• Alexanian, R. and Dimopoulos, M. (1994). The treatment of multiple myeloma, N Engl J Med, 330, 484–489.
   PubMed Web of Science ®Google Scholar